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ABSTRACT
Objectives: To evaluate the effectiveness of
varenicline for smoking cessation in Chinese smokers
in a real world cessation clinic practice.
Design: A prospective observational study.
Setting: Beijing, China.
Participants: A total of 924 smokers (883 men and
41 women) who attended a smoking cessation clinic of
a large general hospital were assessed with data from
structured questionnaires at baseline and follow-up at
1, 3 and 6 months. Trained physician counsellors
provided free individual counselling for all subjects
and follow-up interviews with brief counselling. 332
subjects additionally prescribed varenicline according
to their own choice were compared with those without
varenicline.
Main Outcome Measures: Primary outcomes were
self-reported 7-day point prevalence abstinence rate
and 3-month continuous abstinence rate at 6-month
follow-up. Secondary outcomes were 7-day point
prevalence abstinence rates at 1 and 3-month follow-
up, and 1-month continuous abstinence rate at
3-month follow-up.
Results: By intention-to-treat, the 7-day point
prevalence abstinence rate with varenicline and
counselling at 6 months was significantly higher than
counselling only (37.0% vs 23.1%; OR, 1.75; 95% CI
1.46 to 2.62; p=0.001). The 3-month continuous
abstinence rate at 6 months was higher with varenicline
(33.1% vs 18.4%; OR, 2.04; 95% CI 1.61 to 2.99;
p<0.001). Varenicline also showed better secondary
outcomes.
Conclusions: Varenicline prescription in the smoking
cessation clinic appeared to be effective with doubling
of quit rates in Chinese smokers in a real world
cessation clinic practice.
Clinical trial registration: NCT01935505; Results.
INTRODUCTION
Tobacco kills half of long-term smokers and,
every year, more than 500 million people
worldwide die from tobacco-related diseases.1
In 2010, the China National Prevalence
Survey found that 52.9% of men and 2.4% of
women were current smokers, and 85.6%
current smokers smoked daily. In 2010, there
were an estimated 301 million current
smokers in China, making this country the
largest consumer of tobacco in the world.2
But China is only at the early stage of the
tobacco epidemic and the burden of disease
caused by smoking will increase greatly in
the next few decades.
The most effective way of reducing the
tobacco toll is smoking cessation. In China, cur-
rently approved medications for smoking cessa-
tion include nicotine replacement therapy
(NRT), bupropion sustained release (SR) and
a selective α4β2 nicotinic acetylcholine receptor
partial agonist, varenicline tartrate. Speciﬁcally
developed for smoking cessation, varenicline
ﬁrst showed superior efﬁcacy versus bupropion
SR and placebo in randomised controlled trials
(RCTs) in the West.3 4 Several RCTs conducted
Strengths and limitations of this study
▪ There is strong evidence confirming the effect-
iveness of varenicline on smoking cessation in
many randomised controlled trial studies,
however, prospective evidence on the effective-
ness of varenicline in actual clinical practice,
especially with a control group, in Chinese (Asia
and other Western countries) in a real world
setting is scarce.
▪ Compared to brief counselling alone, varenicline
prescription in the smoking cessation clinic
appeared to be effective, with doubling of quit
rates in Chinese smokers in a real world cessa-
tion clinic practice.
▪ The study provides, for the first time, information
on the effectiveness of different interventions
including varenicline and counselling in a real
world smoking cessation clinic of a large general
hospital in China.
▪ The quit rate was based on self-report by trained
research assistants using a well-constructed and
validated questionnaire, it may have limited valid-
ity and reliability.
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later in six Asian countries, including China, also showed
that varenicline had greater smoking abstinence rates than
placebo.5–7 A meta-analysis of various nicotine receptor
partial agonists (including cytisine, dianicline and vareni-
cline) found that varenicline at standard dose was superior
to bupropion SR and placebo as a smoking cessation aid.8
While RCTs have excellent internal validity, their exter-
nal validity is limited, in particular, by their inclusion
and exclusion criteria, exclusion of subjects with some
diseases, and the additional attention and better adher-
ence of the subjects. The effectiveness in real world
practice often appears to be lower. Reports of effective-
ness from a real world setting are scarce.
The 1996 China National Survey showed that 71.8% of
smokers did not want to quit smoking, 16.6% of smokers
intended to quit, but had not taken any action, 11.6%
who had smoked daily had quit smoking but relapsed
later and only 3.6% smokers had successfully quit for
more than 2 years.9 A systematic literature review showed
that success rates among smokers who attempt to
stop smoking by themselves are low: only 3–5% at 6–12
months after initiating a cessation attempt.10 The 2010
Global Adult Tobacco Survey in China showed that,
among those who had attempted to quit during the past
12 months, 91.8% did not use any method to assist
smoking cessation. Only 33.9% of smokers who had
seen a doctor in the past year had cessation advice from
the doctor.2
Although there is evidence on the effectiveness of var-
enicline in Chinese people in an RCT5 and in an obser-
vational study,11 we found no report on the effectiveness
of varenicline in actual clinical practice with a Chinese
control group in a real world setting. The aim of the
present study was to assess the effectiveness of vareni-
cline for smoking cessation in a real world practice of a
smoking cessation clinic (SCC) in Beijing, China.
METHODS
Study setting and participants
A SCC in the outpatient department of PLA General
Hospital was set up in October 2008 and has continued
to the present. The hospital has about 12 000 outpati-
ents per day. The clinic has 4 weekday evening sessions
(Monday to Thursday from 6:30 to 9:00 pm).
Initially, five part time physicians were trained and
qualiﬁed as smoking cessation counsellors after passing
an examination, similarly to a previous procedure
reported in Hong Kong.12 These physicians provide free
individual counselling to all participants. Exhaled air
carbon monoxide test is also tested at no charge.
In our study, the subjects were current smokers who
were local or non-local residents from different parts of
the country. They came to the SCC directly or called the
SCC booking hotline to make an appointment and ﬁrst
visited the SCC from 28 October 2008 to 31 March
2014. All subjects were willing to quit smoking and
signed an informed consent form. At the ﬁrst visit, those
who were unwilling to participate in the follow-up survey
were excluded. The details of the set-up and operation
of the SCC has been described previously.13
Eight hundred and eighty-three men and 41 women,
aged 17–79 years, who were smoking one or more cigar-
ettes daily and wanted to stop smoking, were eligible.
Those using bupropion SR (n=131) and NRT (n=21)
were excluded. Of the 924 participants included, 182
(21%) were lost to follow-up at 6 months (ﬁgure 1).
Data collection
The baseline and follow-up questionnaires were devel-
oped with reference to the Hong Kong clinic, and other
widely used and validated questionnaires, with about 40
closed-ended questions.12 14 The baseline questionnaire,
completed at the ﬁrst SCC visit, included demographic
characteristics such as age, sex, marital status and educa-
tion level, perceived health status in the past 3 months
and smoking history such as level of smoking, pack-years
of smoking and the number of prior quit attempts. The
level of nicotine addiction was based on the Fagerström
Questionnaire.15 Motivation of quitting was measured by
asking the smokers how important it was for them to
quit smoking, on a scale of 1–100 (1 being least import-
ant and 100 being most important). Responses were
categorised into more important (scoring above the
mean) and less important (scoring below the mean).
Similar questions were asked to measure perceived conﬁ-
dence and difﬁculty in quitting.14 16
Other information collected included tobacco-related
diseases, history of drug, alcohol or physical activity and
willingness to pay for quitting. Exhaled air carbon mon-
oxide level at ﬁrst visit was measured using the ‘Bedfont
Micro II Smokerlizer’. Height, weight, blood pressure,
and waist and hip circumference, were also recorded.
Interventions
At the ﬁrst visit, the interview for the baseline question-
naire was conducted face-to-face, and the process
allowed the smokers to reﬂect on their smoking and
quitting experiences, and gave the physician a better
understanding of the smokers, to guide the counselling.
Smoking cessation counselling for 30–40 min was then
provided for all smokers.
Counselling clues were devised from the needs of indi-
vidual smokers, their smoking status, physical depend-
ency level and tobacco related diseases. The physician
adopted a non-directive approach based on the
Prochaska transtheoretical model.17 It included the ﬁve
‘A’s’ (ask, advise, assess, assist and arrange), assessing
the stage of readiness in quitting smoking, strengthening
smokers’ motivation to quit smoking using the ﬁve ‘R’s’
(relevance, risks, rewards, roadblocks and repetition)
approach. The dangers of smoking as well as the impact
on the smokers’ existing disease and the beneﬁts of quit-
ting were reviewed, and the smokers’ knowledge and
potential barriers to smoking cessation were assessed.
Behavioural self-management techniques to prevent
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relapse, and methods to overcome physiological craving,
psychological dependence and social–cultural factors
with tobacco dependency, were also discussed.
The ﬁnal step described how to quit smoking.
Communication between physicians and smokers is
necessary in order to develop a cessation programme to
ﬁt each smoker. At the early stage (about 2 years) of the
SCC, the physicians would recommend medications for
smokers who smoked heavily, with severe nicotine
dependence and lack of conﬁdence in quitting. Based
on the early experience of using varenicline, the
physicians had a better understanding of its cessation
efﬁciency, and would recommend varenicline for each
smoker as an aid to smoking cessation. The price of the
Starting Box, which is used for 2 weeks, is 263 RMB (US
$1=6.25 RMB), and the price of the Continuing Box,
also used for 2 weeks, is 352 RMB.
The cost of the full course (12 weeks) treatment is
about 2000 RMB (1 Starting Box +5 Continuing Boxes).
Since smoking cessation is not covered by statutory
health insurance in China, the cost of the drugs used in
our study was paid for by the smokers. Due to the high
Figure 1 Subject disposition. NRT, nicotine replacement therapy.
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price of varenicline, some smokers declined it. In the
SCC, the physician would respect the choice of the
smoker. Thus, the smokers were divided into two groups
according to individual choices: those who received
counselling and varenicline were categorised into the
varenicline group, and the others who received counsel-
ling only were the comparison counselling-only group.
Medications were prescribed at the ﬁrst visit. Smokers
who started treatment with varenicline were instructed
to take their ﬁrst dose the following day. Varenicline was
titrated to full dosage over 1 week (0.5 mg once daily for
days 1–3; 0.5 mg twice a day for days 4–7; then 1 mg
twice a day thereafter). Treatment duration was not man-
datory and depended on the choice of the smoker.
Follow-up
Follow-up assessment was made at 1, 3 and 6 months
after the ﬁrst visit. Only a minority of smokers (<5%)
returned to the SCC at the scheduled time for follow-up.
Some subjects receiving varenicline would visit the SCC
irregularly for the prescription, and brief face-to-face
personalised counselling (20–30 min) was given at each
visit. Those who did not return were followed up over
the telephone by physicians or by a specially trained
counsellor, with brief telephone counselling (20–
30 min) for each subject.
The follow-up questionnaires were similar at 1, 3 and 6
months, and were shorter than the baseline version. The
following information was collected: self-reported health
status, smoking status, tobacco consumption, whether
having quit or not, quit attempts, withdrawal symptoms,
drug adverse effects and the biggest obstacle to quitting.
Outcomes
The primary outcomes were 7-day point prevalence rate
abstinence and 3-month continuous abstinence rate
(CAR) at 6-month follow-up. The secondary outcomes
were 7-day abstinence point prevalence rates at 1 month
and 3-month follow-up, respectively, as well as 1-month
CAR at 3-month follow-up. Smokers who had quit were
assessed by asking whether they had smoked any cigarette
(a whole cigarette or a puff) during the past 7 days at
1-month, 3-month and 6-month follow-up (point preva-
lence quit rate), and continuous abstinence for 1 month
or 3 months at 3-month and 6-month follow-up (CAR).
The 7-day point abstinence was used as the main
outcome measure based on the US Clinical Practice
Guideline.18 Those who answered ‘no’ were deﬁned as
quitters, with no biochemical validation.
All self-reported adverse events and safety data were
documented. For those who had severe side effects, the
physicians would instruct them to reduce the dosage or
stop the medication.
Statistical analysis
The data were analysed using Statistical Package for
Social Sciences (SPSS) for Windows V.19.0. The baseline
characteristics of smokers were described using
descriptive statistics. The prevalence of quitters by differ-
ent baseline factors was compared with χ2 test or
Fisher’s exact test. Logistic regression modelling was
used to identify independent predictors for quitting (by
enter method) and to estimate adjusted ORs and 95%
CIs. A p value of <0.05 (two tailed) was considered statis-
tically signiﬁcant. All 924 eligible smokers were included
in the analysis by intention-to-treat, and those who had
reached the follow-up time but could not be contacted
were considered as non-quitters.
RESULTS
Subject disposition
Of 1076 smokers who visited the SCC from 28 October
2008 to 31 March 2014, 924 were eligible and included
(ﬁgure 1). Of these subjects, 61% (562/924) were non-
residents, and the follow-up was carried out mainly by tele-
phone. The 6-month follow-up rate was 76% (451/592)
for counselling, and 88% (292/332) for varenicline.
Overall, 95% of the subjects were men and the mean
age was 41 years (SD=10.6 years). Varenicline was pre-
scribed to 332 (36%) subjects. Table 1 shows that the
varenicline group consumed more cigarettes per day
(p<0.001), had a higher Fagerström score (p<0.001)
and had made more past quit attempts (p=0.014).
There were no signiﬁcant differences in age, gender,
education, the age of the subject when he/she began
smoking and number of years of smoking.
Effectiveness
At 1-month, 3-month and 6-month follow-up, the self-
reported 7-day point prevalence abstinence rates and
CARs were signiﬁcantly higher in the varenicline plus
counselling group than in the counselling-only group.
The primary outcomes at 6-month follow-up are
shown in ﬁgure 2. The 7-day point prevalence abstin-
ence rate with varenicline was signiﬁcantly higher than
that of counselling only: 37.0% versus 23.1% (OR, 1.96;
95% CI 1.46 to 2.62; p<0.001). Also, the 3-month CAR
with varenicline was higher, 33.1% versus 18.4% (OR,
2.20; 95% CI 1.61 to 2.99; p<0.001).
The secondary outcomes are shown in table 2. The
7-day point prevalence abstinence rates with varenicline
were all greater than those of counselling only: 40.1%
versus 18.6% (OR, 2.93; 95% CI 2.17 to 3.96; p<0.001)
at 1 month, and 38.0% versus 22.6% (OR, 2.01; 95% CI
1.56 to 2.80; p<0.001) at 3 months. The continuous
1-month quit rate at 3 months was also higher: 36.1%
versus 18.4% (OR, 2.51; 95% CI 1.85 to 3.40).
Of 332 subjects who were prescribed varenicline, 52%
reported that they had used varenicline for less than
4 weeks, 40% for 4–8 weeks and 8% for 9 weeks or
more. Table 3 shows that the 3-month CAR at 6 months
showed an increasing but nonsigniﬁcant trend with the
duration of drug use (p for trend=0.085). Using vareni-
cline for 9 weeks or more showed much higher 3-month
CAR with marginal statistical signiﬁcance.
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Safety and tolerability
Throughout the observation period, varenicline was safe
and generally well tolerated. Among the 332 users, 24%
(95% CI 20% to 29%) reported adverse events or side
effects (table 4). The most frequent were gastrointestinal
disorders (12.7%), psychiatric disorders (2.7%: all were
sleep disorders), nervous system disorders (3.3%: dizzi-
ness) and cardiovascular system disorders (2.4%: palpita-
tion). For gastrointestinal disorders, nausea was the most
commonly reported (9.6%), followed by ﬂatulence
(2.4%). The nausea was mostly mild to moderate and
diminished over time. No deaths occurred during the
treatment and follow-up. Five single serious adverse
events (1.5%) were recorded during follow-up: severe
nausea in 3 subjects and dizziness in 2 subjects.
Twenty-six (7.8%) users discontinued quitting and 15
(4.5%) reduced the dose of varenicline due to adverse
events.
Predictors of quitting
At baseline, 18 factors were chosen in the analysis of pre-
dictors of quitting, including demographic character-
istics, tobacco use-related factors and varenicline.
Demographic characteristics included age, gender,
marital status, education and household income per
month. Tobacco use-related factors included age at initi-
ation of smoking, cigarettes smoked daily, on average,
number of years of smoking, CO level, number of past
quit attempts, length of abstinence in the last quit
attempt, stage of readiness in quitting, perceived import-
ance, perceived difﬁculty and perceived conﬁdence in
Table 1 Baseline demographic characteristics and smoking history of study participants, by counselling group and
counselling+varenicline group
Counselling (n=592) Counselling+varenicline (n=332) p Value
Age, mean (SD), years 41.2±11.2 41.3±9.8 0.898
Gender, Number (%)
Male 568 (95.9) 315 (94.9) 0.506
Female 24 (4.1) 17 (5.1)
Education, Number (%)
High school and below 263 (44.4) 146 (44.0) 0.945
College and above 329 (55.6) 186 (56.0)
Age began smoking, mean (SD) 19.4±5.2 19.4±4.4 0.953
Number of years smoked, mean (SD) 21.4±10.7 21.3±9.7 0.864
Number of cigarettes/day over past 1 month,
mean (SD)**
20.4±11.2 22.2±11.9 0.017
Fagerström score†, mean (SD) 5.1±2.5 6.0±2.5 <0.001
≥1 previous quit attempt, n (%) 441 (74.5) 269 (81.0) 0.028
Age, mean (SD), years 41.2±11.2 41.3±9.8 0.90
Gender, n (%)
Male 568 (95.9) 315 (94.9) 0.51
Female 24 (4.1) 17 (5.1)
Education, n (%)
High school and below 263 (44.4) 146 (44.0) 0.96
College and above 329 (55.6) 186 (56.0)
Age began smoking, mean (SD) 19.4±5.2 19.4±4.4 0.95
No of years smoked, mean (SD) 21.4±10.7 21.3±9.7 0.86
No of cigarettes/day over past 1 month, mean (SD)** 20.4±11.2 22.2±11.9 <0.05
Fagerström score†, mean (SD)* 5.1±2.5 6.0±2.5 <0.001
≥1 previous quit attempt, No (%)** 441 (74.5) 269 (81.0) <0.05
*p<0.001.
**p<0.05.
†Range, 0 to 10. Higher scores indicate greater dependence.
Figure 2 Primary outcomes at 6-month follow-up for 7-day
point prevalence abstinence rate (7-day PPAR) and 3-month
continuous abstinence rate (3-month CAR). CI OR. CAR,
continuous abstinence rate; PPAR, point prevalence
abstinence rate.
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quitting, tobacco related diseases, spouse smoking and
drinking.
Table 5 shows that varenicline (OR, 2.1, 95% CI 1.49
to 2.96, p<0.001), higher daily cigarette consumption
and more conﬁdence in quitting were signiﬁcant inde-
pendent predictors of quitting. The results were similar
after excluding all those who did not return for
follow-up.
DISCUSSION
This is the ﬁrst real world observational study showing a
doubling of smoking abstinence from varenicline in
Chinese smokers in a SSC in China. We did not have a
sample size calculation but the paper is based on the
largest series of such smokers in China.
The strengths of our study were: (1) having a
counselling-only comparison group and (2) a longer
follow-up period of 6 months.
Few studies have examined the effect of varenicline on
smoking cessation in a real world practice in Mainland
China, Hong Kong and Taiwan. In China, Liang et al19
observed 25 subjects in their clinical practice and
reported that the abstinence rate continuously for
4 weeks (9–12 weeks) with varenicline was 48% at
12 weeks of follow-up, and that the CARs for longer
(8–12 weeks) treatment times were higher than those
for shorter (<8 weeks) treatment times (p=0.027). But
there was no comparison or control group.
Studies of the effectiveness of varenicline in real
world clinics were scarce, compared to RCTs. Dhelaria
et al20 conducted a retrospective cohort study at 2
urban academic health centres in the USA, and found
that 10.2% patients who received varenicline and had
at least one follow-up visit maintained abstinence
through 1 year at the 52-week follow-up. Assuming
those who had no follow-up had not quit, the overall
quit rate was only 6.4%. Blak et al also conducted a
retrospective study in a UK general practice setting.
They identiﬁed varenicline users from records in The
Health Improvement Network database, and sent a
questionnaire to patients who commenced smoking ces-
sation treatment close to the selection date (6 months
prior to the date of questionnaire dispatch), and the
overall 7-day point prevalence abstinence rate was
49.5% (after 6 months since starting varenicline). But
this study had only 193 responses and a low response
rate of 26.4%.21 In an inter-Asian 12-week, prospective,
observational, non-comparative varenicline trial, the
proportion of subjects in China with an abstinence
status of ‘Quit’ before week 12 was 57.1% (95% CI
53.55% to 60.65%).11 A varenicline phase IV trial in
Germany showed that the 7-day abstinence rate
between weeks 11 and 12 was 71.1% (95% CI 68.5% to
73.7%).22 In another 12-week, prospective, observa-
tional, non-comparative trial of varenicline in four
European countries (Belgium, Greece, Hungary and
Slovenia), the 7-day point prevalence abstinence rate at
Table 2 Secondary outcomes of 7-day PPAR and 1-month CAR at 1-month and 3-month follow-up (n=924)
Follow-up Quitting rates % (n) OR (95% CI) p Value
7-day PPAR at 1 month
Varenicline 40.1 (133/332) 2.93 (2.17 to 3.96) <0.001
Counselling 18.6 (110/592) 1.00
7-day PPAR at 3-month
Varenicline 38.0 (126/332) 2.01 (1.56 to 2.80) <0.001
Counselling 22.6 (134/592) 1.00
1-month CAR at 3-month
Varenicline 36.1 (120/332) 2.51 (1.85 to 3.40) <0.001
Counselling 18.4 (109/592) 1.00
CAR, continuous abstinence rate; PPAR, point prevalence abstinence rate.
Table 3 Quitting rates related to varenicline duration at 6-month follow-up (n=332)
Duration of varenicline Quitting rates % (n) OR (95% CI) p Value* p for Trend OR (95% CI) p Value†
7-day PPAR
≥9 weeks 56.0 (14/25) 2.48 (1.06 to 5.80) 0.036 0.067 2.11 (0.89 to 5.01) 0.090
4–8 weeks 40.7 (50/133) 1.17 (0.73 to 1.88) 0.504 1.00
<4 weeks 33.9 (59/174) 1.00
3-month CAR
≥9 weeks 48.0 (12/25) 2.17 (0.93 to 5.06) 0.074 0.085 1.75 (0.74 to 4.13) 0.205
4–8 weeks 34.6 (46/133) 1.24 (0.77 to 2.01) 0.382 1.00
<4 weeks 29.9 (52/174) 1.00
*Compared with subjects receiving varenicline <4 weeks.
†Compared with subjects receiving varenicline 4–8 weeks.
CAR, continuous abstinence rate; PPAR, point prevalence abstinence rate.
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week 12 was 64.6% (95% CI 60.1% to 68.3%).23 All the
quit rates were based on self reporting only and with
short follow-up. None of the studies had a control or
comparison group with no varenicline. Our quit rate in
motivated smokers seeking help was lower than those
mentioned above but could be higher than those in
the community who did not seek help.
Of the papers cited above, the latter four, which had
very high quit rate, were planned and sponsored by
Pﬁzer Inc.11 21–23 In the observational trial conducted in
China, the 7-day quit rate over a 7-day period was 57.1%,
but the quit rates of some subjects were assessed with
less than 12 weeks of follow-up.11 In our study, the 7-day
point prevalence abstinence rate with varenicline
reached 38.0% at 3-month follow-up, which appeared to
be lower, but our data were all collected at 3-month
follow-up. In addition, these observational studies
sponsored by Pﬁzer had only followed up for 12 weeks,
we had a longer follow-up of 6 months. The 7-day point
prevalence abstinence rate and 3-month CAR was 37.0%
and 33.1%, respectively, at 6-month follow-up, both sig-
niﬁcantly higher than those of counselling.
There were many RCTs conﬁrming the effectiveness
of varenicline. A meta-analysis by Cahill et al8 included
RCTs that compared the treatment drug with placebo,
excluding trials with less than 6 months of follow-up.
They concluded that varenicline at standard dose
increased long-term smoking cessation by two fold. The
pooled RR for continuous or sustained abstinence at
6 months or longer for varenicline at standard dosage
versus placebo was 2.27 (95% CI 2.02 to 2.55; 14 trials,
6166 people). At lower or variable doses, the RR was
2.09 (95% CI 1.56 to 2.78; 4 trials, 1272 people). In the
present study, the OR for 3-month continuous abstin-
ence at 6 months for varenicline versus counselling was
2.04, which was similar to that above pooled RR.
Compared to the RCT that included Chinese
smokers,5 our 7-day point prevalence (63.0% (week 12)
in RCT versus 38.0% (month 3)) and CARs (50.3%
(9–12 weeks) in RCT versus 36.1% (2–3-month)) were
substantially lower in a real world clinical practice. Two
factors might account for the discrepancy: (1) subjects
in RCTs were usually more highly motivated with better
adherence and had more attention from the researchers
and counsellors; (2) subjects in RCTs received a full
course of 12 weeks free, but our subjects were seldom
prescribed the full course because of the high cost, and
over worries about side effects. In the present study, only
4% were prescribed varenicline for 9–12 weeks.
In addition to varenicline, we found two independ-
ent predictors of quitting: lower daily cigarette con-
sumption and greater conﬁdence in quitting. The
former indicates a lower nicotine dependence and
has often been found to be an important pre-
dictor.24–26 The latter suggests that counsellors should
aim at enhancing conﬁdence and self efﬁcacy. Future
studies should examine whether increased conﬁdence
could be a mediator between varenicline prescription
and quitting. Education was not a predictor of the
use of varenicline. In China, high levels of education
do not necessarily relate to high incomes. Moreover,
the price of medications is not the only factor that
determines the choice of drugs. Many subjects did
Table 4 All-causality, treatment-emergent adverse events
(AE) among subjects receiving varenicline
Varenicline
(n=332)
No (%)
Any adverse event 80 (24.1)
Most frequent AE
Gastrointestinal disorders 42 (12.7)
Nausea 32 (9.6)
Dry mouth 1 (0.3)
Flatulence 8 (2.4)
Diarrhoea 1 (0.3)
Psychiatric disorders 9 (2.7)
Abnormal dreams 2 (0.3)
Sleep disorder 2 (0.3)
Insomnia 5 (1.5)
Nervous system disorders
Dizziness 9 (3.3)
Cardiovascular system disorders
Palpitation 8 (2.4)
Respiratory system disorders
Cough 2 (0.6)
General disorders
Itching 7 (2.1)
Serious adverse events 5 (1.5)
Quitting discontinuation due to AE 26 (7.8)
Dose reduction or temporary discontinuation
due to AE
15 (4.5)
Table 5 Summary of logistic regression (enter) model to predict quitting smoking
Independent variables OR* (95% CI) OR† (95% CI)
Received varenicline treatment 2.22 (1.60 to 3.08)‡ 2.10 (1.49 to 2.96)‡
More cigarettes smoked on average daily§ 1.56 (1.12 to 2.18)¶ 1.56 (1.10 to 2.21)¶
More confidence in quitting, per score 1.49 (1.05 to 2.10)¶ 1.53 (1.07 to 2.20)¶
*Including those who did not return for follow-up as non-quitters, n=924.
†Excluding those who did not return for follow-up, n=743.
‡χ2 test, p<0.001.
§Cigarettes smoked on average daily is defined as 20 cigarette/day.
¶χ2 test, p<0.05.
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not choose varenicline because of concerns about
side effects.
The present study also conﬁrmed that varenicline was
safe and generally well tolerated in Chinese smokers. The
overall self-reported adverse event rate was 24.1%, which
is similar to 28.1% in the inter-Asian observational
study.11 Adverse event rate of varenicline in most RCTs
was higher: 78.4% in smokers in the US,3 77% in smokers
in China, Singapore and Thailand,5 86.5% in smokers in
Taiwan and Korea,6 and 80.1% in smokers in Japanese.7
The lower rate in the present study could be due to the
much shorter duration of treatment and/or
under-reporting.
Our study had some limitations. First, the subjects of
the two groups were not similar. The varenicline group
could be more motivated as they were willing to pay the
high cost of the drug. Second, because most subjects
were not local residents, most of the follow-up was
carried out by telephone interview, and the quit rate was
based on self-reporting. Third, the duration of medica-
tion varied with different and unveriﬁed adherence.
Fourth, our results were up to 6-month follow-up. We
shall continue to follow-up at 1 year and beyond. Finally,
the 24% loss in follow-up rate of the counselling group
was signiﬁcantly higher than the 12% of the varenicline
group (p=0.013). But the results of both 7-day point
prevalence abstinence rate and CAR were similar after
excluding all those who did not return for follow-up;
only the values of OR were slightly lower and a p value
slightly increased. Fifth, our loss to follow-up rate was
21%. Previous varenicline papers showed that 26.4%21 to
29%27 were lost to follow-up. Our intention-to-treat ana-
lysis assumed those lost to follow-up had not quit, as
most of them had low intention to quit (some came
only under pressure from family members, others’ inten-
tion to quit reduced after going back to their living and
working environments, and some relapsed). This group
most likely would refuse follow-up by telephone. Hence,
the loss to follow-up rate and intention-to-treat analysis
should not have affected the results (by over- or under-
estimating the quit rates) substantially.
The present study is important because it provides, for
the ﬁrst time, information on the effectiveness of differ-
ent interventions including varenicline and counselling
in a real world SSC of a large general hospital in China.
Having a counselling group as a comparison group in
this study, which was not seen in other observational
studies, is a most signiﬁcant advantage.
Our ﬁndings suggest that varenicline should have a
major role in smoking cessation in China but its cost is
high, and smoking cessation counselling and medica-
tions are not covered by statutory health insurance in
China. The prescription and use of the drug is
extremely low in routine clinical settings and in SSCs.
We recommend that the price of the drug be reduced to
encourage more physicians to prescribe and more
smokers to use varenicline, and that the drug be covered
by health insurance.
CONCLUSION
Compared to brief counselling alone, varenicline pre-
scription with brief counselling in a SSC appeared to be
effective, with doubling of quit rates in Chinese smokers
in a real world cessation clinic practice in China.
Author affiliations
1Nanlou Faculty of Clinical Medicine, Department of Traditional Chinese
Medicine and Acupuncture, Chinese People’s Liberation Army General
Hospital, Beijing, China
2Department of Epidemiology, Institute of Geriatrics, Beijing key laboratory of
Aging and Geriatrics, Chinese People’s Liberation Army General Hospital,
Beijing, China
3Nanlou Faculty of Clinical Medicine, Department of Respiration, Chinese
People’s Liberation Army General Hospital, Beijing, China
4Nanlou Faculty of Clinical Medicine, Department of Rehabilitation, Chinese
People’s Liberation Army General Hospital, Beijing, China
5Public Health, Epidemiology and Biostatistics, University of Birmingham,
Birmingham, UK
6School of Nursing, School of Public Health, The University of Hong Kong,
Hong Kong, China
7Department of Community Medicine, School of Public Health and The
University of Hong Kong, Hong Kong, China
Acknowledgements The authors thank LX, JHZ and JF for research
assistance in the follow-up interviews.
Contributors YH, BJ and THL designed the study and analysed the data. BJ,
FZ, Q-HL, C-XZ, LZ and LW contributed to data collection and field
operations. THL, SSCC and KKC contributed to the setting up of the clinic and
design of the interventions, and provided training. BJ and YH took final
responsibility for the decision to submit for publication.
Funding This study was supported by research grants from the National
Natural Science Foundation of China, 81373080; Beijing Municipal Science
and Technology Commission, Z121107001012070; Cancer Research UK:
Smoking cessation and advocacy training among health professionals in
Beijing and Guangzhou, China, C1343/A10155.
Competing interests None declared.
Patient consent Obtained.
Ethics approval This project was approved by the Ethics Committee of the
PLA General Hospital in China.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Kaleta D, Koziel = A, Miskiewicz P. MPOWER—strategy for fighting
the global tobacco epidemic. Med Pr 2009;60:145–9.
2. Li Q, Hsia J, Yang GH. Prevalence of smoking in China in 2010.
N Engl J Med 2011;364:2469–70.
3. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an
alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus
sustained-release bupropion and placebo for smoking cessation:
a randomized controlled trial. JAMA 2006;296:47–55.
4. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an
alpha4beta2 nicotinic acetylcholine receptor partial agonist, versus
placebo or sustained-release bupropion for smoking cessation:
a randomized controlled trial. JAMA 2006;296:56–63.
5. Wang C, Xiao D, Chan KP, et al. Varenicline for smoking cessation:
A placebo-controlled, randomized study. Respirology
2009;14:384–92.
8 Jiang B, et al. BMJ Open 2016;6:e009381. doi:10.1136/bmjopen-2015-009381
Open Access
group.bmj.com on January 20, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
6. Tsai ST, Cho HJ, Cheng HS, et al. A randomized, placebo-controlled
trial of varenicline, a selective a4b2 nicotinic acetylcholine receptor
partial agonist, as a new therapy for smoking cessation in Asian
smokers. Clin. Ther 2007;29:1027–39.
7. Nakamura M, Oshima A, Fujimoto Y, et al. Efficacy and tolerability of
varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist,
in a 12-week, randomized, placebo-controlled, dose-response study
with 40-week follow-up for smoking cessation in Japanese smokers.
Clin Ther 2007;29:1040–56.
8. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for
smoking cessation. Cochrane Database Syst Rev 2012;4:
CD006103.
9. Yang G, Ma J, Chen A, et al. Smoking cessation in China: findings
from the 1996 national prevalence survey. Tob Control
2001;10:170–4.
10. Hughes JR, Keely J, Naud S. Shape of the relapse curve and
long-term abstinence among untreated smokers. Addiction
2004;99:29–38.
11. Wang C, Cho B, Xiao D, et al. Effectiveness and safety of
varenicline as an aid to smoking cessation: results of an inter-Asian
observational study in real-world clinical practice. Int J Clin Pract
2013;67:469–76.
12. Abdullah AS, Hedley AJ, Chan SS, et al, Hong Kong Council on
Smoking and Health Smoking Cessation Health Centre (SCHC)
Steering Group. Establishment and evaluation of a smoking
cessation clinic in Hong Kong: a model for the future service
provider. J Public Health (Oxf) 2004;26:239–44.
13. He Y, Lam TH, Jiang B, et al. Study design and the preliminary
results on the modes of smoking cessation in general hospitals.
Chin J Epidemiol 2011;32:192–5.
14. Lam TH, Abdullah AS, Chan SS, et al. Adherence to nicotine
replacement therapy versus quitting smoking among Chinese
smokers: a preliminary investigation. Psychopharmacology (Berl)
2005;177:400–8.
15. Fagerstrom KO, Heatherton TF, Kozlowski LT. Nicotine addiction
and its assessment. Ear Nose Throat J 1990;69:763–5.
16. Zhu WH, Yang L, Jiang CQ, et al. Characteristics of smokers and
predictors of qutting in a smoking cessation clinic in Guangzhou,
China. J Public Health (Oxf) 2010;32:267–76.
17. Prochaska JO, Goldstein MG. Process of smoking
cessation. Implications for clinicians. Clin Chest Med
1991;12:727–35.
18. Fiore MC. US public health service clinical practice guideline:
treating tobacco use and dependence. Respir Care
2000;45:1200–62.
19. Liang DH, Liu H, Wei CZ. Clinical observation of
varenicline for smoking cessation. Chin J New Clin Med
2011;4:1161–2.
20. Dhelaria RK, Friderici J, Wu K, et al. Effectiveness of varenicline for
smoking cessation at 2 urban academic health centers. Eur J Intern
Med 2012;23:461–4.
21. Blak BT, Wilson K, Metcalfe M, et al. Evaluation of varenicline as an
aid to smoking cessation in UK general practice—a THIN database
study. Curr Med Res Opin 2010;26:861–70.
22. Andreas S, Chenot JF, Diebold R, et al. Effectiveness of Varenicline
as an Aid to Smoking Cessation in Primary Care: An Observational
Study. Eur Addict Res 2013;19:47–54.
23. Boudrez H, Gratziou C, Messig M, et al. Effectiveness of
varenicline as an aid to smoking cessation: Results of an inter-
European observational study. Curr Med Res Opin 2011;27:
769–75.
24. Razavi D, Vandecasteele H, Primo C, et al. Maintaining abstinence
from cigarette smoking: effectiveness of group counselling and
factors predicting outcome. Eur J Cancer 1999;35:1238–47.
25. Hyland A, Li Q, Bauer JE, et al. Predictors of cessation in a cohort
of current and former smokers followed over 13 years. Nicotine Tob
Res 2004;6(Suppl 3):S363–9.
26. Hymowitz N, Cummings KM, Hyland A, et al. Predictors of smoking
cessation in a cohort of adult smokers followed for five years.
Tob Control 1997;6(Suppl. 2):S57–62.
27. Ebbert JO, Hughes JR, West RJ, et al. Effect of varenicline on
smoking cessation through smoking reduction: a randomized clinical
trial. JAMA 2015;313:687–94.
Jiang B, et al. BMJ Open 2016;6:e009381. doi:10.1136/bmjopen-2015-009381 9
Open Access
group.bmj.com on January 20, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
cohort study in China
for smoking cessation in an observational 
Effectiveness of varenicline and counselling
Zhou, K K Cheng, Sophia S C Chan and Tai Hing Lam
Bin Jiang, Yao He, Fang Zuo, Lei Wu, Qing-Hui Liu, Li Zhang, Chang-Xi
doi: 10.1136/bmjopen-2015-009381
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/1/e009381
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/1/e009381
This article cites 27 articles, 5 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (170)Smoking and tobacco
 (1354)Public health
 (401)General practice / Family practice
 (101)Addiction
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on January 20, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
